Site Initiation Occurred for New Alzheimer Disease Trial
The primary purpose of this study is to evaluate the effect of a new medication versus placebo on cognitive decline using the Alzheimer’s Disease Assessment Scale Cognitive subscale 13‑item version (ADAS-Cog13). Contact us to learn more.
More Information
The primary purpose of this study is to evaluate the effect of a new medication versus placebo on cognitive decline using the Alzheimer’s Disease Assessment Scale Cognitive subscale 13‑item version (ADAS-Cog13). Contact us at (617) 302 6388 to learn more.
LOCATIONS
Locations in:
United States, Japan, Canada, Australia, Spain, Belgium, Netherlands, France, Sweden